Glaukos Advances Phase 3 Glaucoma Implant Trial, Keeping GKOS in Focus for Investors

Glaukos Corp. (GKOS) announced an update on their ongoing clinical study.

Glaukos Corp. (GKOS) is running a new late-stage study called “Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (Travoprost Intraocular Implant) in Conjunction With the Placement of iStent Infinite vs. iStent Infinite Alone in Subjects With Open-angle Glaucoma or Ocular Hypertension.” The goal is to see whether adding the iDose TR implant to iStent infinite surgery, or using iDose TR alone, can better control eye pressure in patients with open-angle glaucoma or high eye pressure, a large and growing market in eye care.

The study is testing Glaukos’ travoprost intraocular implant, branded as iDose TR, and the company’s iStent infinite device. iDose TR is a tiny, long-acting drug implant placed inside the eye to slowly release glaucoma medication over time. iStent infinite is a micro-stent system already used in eye surgery to improve fluid drainage and lower pressure. The trial compares iDose TR plus iStent infinite, iStent infinite with a sham eye procedure, and iDose TR alone with a sham procedure mimicking stent placement.

This is an interventional Phase 3 trial with patients randomly assigned to different treatment paths. One group gets iDose TR plus the iStent infinite device, another gets iStent infinite plus a sham procedure, and a third gets iDose TR alone plus a sham stent procedure. The trial is double-masked, meaning patients and those measuring results do not know who received the real implant or sham. The main goal is treatment-focused: to see which approach gives better and safer control of eye pressure in everyday surgical settings.

The study was first submitted in late September 2023 and is currently listed as recruiting, with patients followed for 12 months after treatment. The most recent update was posted on January 19, 2026, signaling that the protocol and status have been refreshed as the trial moves forward. Key completion dates, including when primary results will be collected and the full study will wrap up, are still ahead, so no outcome data are available yet.

From a market view, this update supports Glaukos’ push to build a broader glaucoma platform that combines devices and sustained-release drug implants. Continued progress in this Phase 3 program can underpin the long-term growth story for GKOS by extending its product life cycle beyond current micro-stent offerings. Positive future data could strengthen Glaukos’ competitive edge against larger ophthalmology players focused on eye drops and other surgical devices, while delays or weak results would likely weigh on sentiment. For now, the active recruitment and recent update should be seen as a steady, though not transformational, catalyst that keeps the glaucoma pipeline front and center in investors’ minds.

The study remains ongoing and recently updated, with fuller details available on the ClinicalTrials.gov portal under the registered identifier.

To learn more about GKOS’s potential, visit the Glaukos Corp. drug pipeline page.